Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801280679> ?p ?o ?g. }
- W2801280679 endingPage "1692" @default.
- W2801280679 startingPage "1683" @default.
- W2801280679 abstract "Background Treatment-resistant major depressive disorder is common; repetitive transcranial magnetic stimulation (rTMS) by use of high-frequency (10 Hz) left-side dorsolateral prefrontal cortex stimulation is an evidence-based treatment for this disorder. Intermittent theta burst stimulation (iTBS) is a newer form of rTMS that can be delivered in 3 min, versus 37·5 min for a standard 10 Hz treatment session. We aimed to establish the clinical effectiveness, safety, and tolerability of iTBS compared with standard 10 Hz rTMS in adults with treatment-resistant depression. Methods In this randomised, multicentre, non-inferiority clinical trial, we recruited patients who were referred to specialty neurostimulation centres based at three Canadian university hospitals (Centre for Addiction and Mental Health and Toronto Western Hospital, Toronto, ON, and University of British Columbia Hospital, Vancouver, BC). Participants were aged 18–65 years, were diagnosed with a current treatment-resistant major depressive episode or could not tolerate at least two antidepressants in the current episode, were receiving stable antidepressant medication doses for at least 4 weeks before baseline, and had an HRSD-17 score of at least 18. Participants were randomly allocated (1:1) to treatment groups (10 Hz rTMS or iTBS) by use of a random permuted block method, with stratification by site and number of adequate trials in which the antidepressants were unsuccessful. Treatment was delivered open-label but investigators and outcome assessors were masked to treatment groups. Participants were treated with 10 Hz rTMS or iTBS to the left dorsolateral prefrontal cortex, administered on 5 days a week for 4–6 weeks. The primary outcome measure was change in 17-item Hamilton Rating Scale for Depression (HRSD-17) score, with a non-inferiority margin of 2·25 points. For the primary outcome measure, we did a per-protocol analysis of all participants who were randomly allocated to groups and who attained the primary completion point of 4 weeks. This trial is registered with ClinicalTrials.gov, number NCT01887782. Findings Between Sept 3, 2013, and Oct 3, 2016, we randomly allocated 205 participants to receive 10 Hz rTMS and 209 participants to receive iTBS. 192 (94%) participants in the 10 Hz rTMS group and 193 (92%) in the iTBS group were assessed for the primary outcome after 4–6 weeks of treatment. HRSD-17 scores improved from 23·5 (SD 4·4) to 13·4 (7·8) in the 10 Hz rTMS group and from 23·6 (4·3) to 13·4 (7·9) in the iTBS group (adjusted difference 0·103, lower 95% CI −1·16; p=0·0011), which indicated non-inferiority of iTBS. Self-rated intensity of pain associated with treatment was greater in the iTBS group than in the 10 Hz rTMS group (mean score on verbal analogue scale 3·8 [SD 2·0] vs 3·4 [2·0] out of 10; p=0·011). Dropout rates did not differ between groups (10 Hz rTMS: 13 [6%] of 205 participants; iTBS: 16 [8%] of 209 participants); p=0·6004). The most common treatment-related adverse event was headache in both groups (10 Hz rTMS: 131 [64%] of 204; iTBS: 136 [65%] of 208). Interpretation In patients with treatment-resistant depression, iTBS was non-inferior to 10 Hz rTMS for the treatment of depression. Both treatments had low numbers of dropouts and similar side-effects, safety, and tolerability profiles. By use of iTBS, the number of patients treated per day with current rTMS devices can be increased several times without compromising clinical effectiveness. Funding Canadian Institutes of Health Research. Treatment-resistant major depressive disorder is common; repetitive transcranial magnetic stimulation (rTMS) by use of high-frequency (10 Hz) left-side dorsolateral prefrontal cortex stimulation is an evidence-based treatment for this disorder. Intermittent theta burst stimulation (iTBS) is a newer form of rTMS that can be delivered in 3 min, versus 37·5 min for a standard 10 Hz treatment session. We aimed to establish the clinical effectiveness, safety, and tolerability of iTBS compared with standard 10 Hz rTMS in adults with treatment-resistant depression. In this randomised, multicentre, non-inferiority clinical trial, we recruited patients who were referred to specialty neurostimulation centres based at three Canadian university hospitals (Centre for Addiction and Mental Health and Toronto Western Hospital, Toronto, ON, and University of British Columbia Hospital, Vancouver, BC). Participants were aged 18–65 years, were diagnosed with a current treatment-resistant major depressive episode or could not tolerate at least two antidepressants in the current episode, were receiving stable antidepressant medication doses for at least 4 weeks before baseline, and had an HRSD-17 score of at least 18. Participants were randomly allocated (1:1) to treatment groups (10 Hz rTMS or iTBS) by use of a random permuted block method, with stratification by site and number of adequate trials in which the antidepressants were unsuccessful. Treatment was delivered open-label but investigators and outcome assessors were masked to treatment groups. Participants were treated with 10 Hz rTMS or iTBS to the left dorsolateral prefrontal cortex, administered on 5 days a week for 4–6 weeks. The primary outcome measure was change in 17-item Hamilton Rating Scale for Depression (HRSD-17) score, with a non-inferiority margin of 2·25 points. For the primary outcome measure, we did a per-protocol analysis of all participants who were randomly allocated to groups and who attained the primary completion point of 4 weeks. This trial is registered with ClinicalTrials.gov, number NCT01887782. Between Sept 3, 2013, and Oct 3, 2016, we randomly allocated 205 participants to receive 10 Hz rTMS and 209 participants to receive iTBS. 192 (94%) participants in the 10 Hz rTMS group and 193 (92%) in the iTBS group were assessed for the primary outcome after 4–6 weeks of treatment. HRSD-17 scores improved from 23·5 (SD 4·4) to 13·4 (7·8) in the 10 Hz rTMS group and from 23·6 (4·3) to 13·4 (7·9) in the iTBS group (adjusted difference 0·103, lower 95% CI −1·16; p=0·0011), which indicated non-inferiority of iTBS. Self-rated intensity of pain associated with treatment was greater in the iTBS group than in the 10 Hz rTMS group (mean score on verbal analogue scale 3·8 [SD 2·0] vs 3·4 [2·0] out of 10; p=0·011). Dropout rates did not differ between groups (10 Hz rTMS: 13 [6%] of 205 participants; iTBS: 16 [8%] of 209 participants); p=0·6004). The most common treatment-related adverse event was headache in both groups (10 Hz rTMS: 131 [64%] of 204; iTBS: 136 [65%] of 208). In patients with treatment-resistant depression, iTBS was non-inferior to 10 Hz rTMS for the treatment of depression. Both treatments had low numbers of dropouts and similar side-effects, safety, and tolerability profiles. By use of iTBS, the number of patients treated per day with current rTMS devices can be increased several times without compromising clinical effectiveness." @default.
- W2801280679 created "2018-05-17" @default.
- W2801280679 creator A5003880874 @default.
- W2801280679 creator A5004751576 @default.
- W2801280679 creator A5013738913 @default.
- W2801280679 creator A5015397147 @default.
- W2801280679 creator A5027291703 @default.
- W2801280679 creator A5029079877 @default.
- W2801280679 creator A5042074794 @default.
- W2801280679 creator A5048377473 @default.
- W2801280679 creator A5051880625 @default.
- W2801280679 creator A5090658899 @default.
- W2801280679 creator A5090699665 @default.
- W2801280679 date "2018-04-01" @default.
- W2801280679 modified "2023-10-16" @default.
- W2801280679 title "Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial" @default.
- W2801280679 cites W1970133878 @default.
- W2801280679 cites W1985193354 @default.
- W2801280679 cites W1985285470 @default.
- W2801280679 cites W1988751658 @default.
- W2801280679 cites W1997945733 @default.
- W2801280679 cites W2004762037 @default.
- W2801280679 cites W2011935138 @default.
- W2801280679 cites W2036630871 @default.
- W2801280679 cites W2039979496 @default.
- W2801280679 cites W2043304523 @default.
- W2801280679 cites W2047256315 @default.
- W2801280679 cites W2052249755 @default.
- W2801280679 cites W2055962587 @default.
- W2801280679 cites W2061378977 @default.
- W2801280679 cites W2062103870 @default.
- W2801280679 cites W2069091142 @default.
- W2801280679 cites W2072118682 @default.
- W2801280679 cites W2073595961 @default.
- W2801280679 cites W2074633014 @default.
- W2801280679 cites W2079418286 @default.
- W2801280679 cites W2083920471 @default.
- W2801280679 cites W2097446825 @default.
- W2801280679 cites W2097950056 @default.
- W2801280679 cites W2107959833 @default.
- W2801280679 cites W2108289758 @default.
- W2801280679 cites W2115504852 @default.
- W2801280679 cites W2124175406 @default.
- W2801280679 cites W2127124395 @default.
- W2801280679 cites W2136137354 @default.
- W2801280679 cites W2140787893 @default.
- W2801280679 cites W2147720794 @default.
- W2801280679 cites W2149154629 @default.
- W2801280679 cites W2156092714 @default.
- W2801280679 cites W2161200711 @default.
- W2801280679 cites W2165041300 @default.
- W2801280679 cites W2287057286 @default.
- W2801280679 cites W2341489800 @default.
- W2801280679 cites W2560565629 @default.
- W2801280679 cites W2562220447 @default.
- W2801280679 cites W2589311751 @default.
- W2801280679 cites W2725272435 @default.
- W2801280679 cites W2761854305 @default.
- W2801280679 cites W4236675028 @default.
- W2801280679 doi "https://doi.org/10.1016/s0140-6736(18)30295-2" @default.
- W2801280679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29726344" @default.
- W2801280679 hasPublicationYear "2018" @default.
- W2801280679 type Work @default.
- W2801280679 sameAs 2801280679 @default.
- W2801280679 citedByCount "618" @default.
- W2801280679 countsByYear W28012806792018 @default.
- W2801280679 countsByYear W28012806792019 @default.
- W2801280679 countsByYear W28012806792020 @default.
- W2801280679 countsByYear W28012806792021 @default.
- W2801280679 countsByYear W28012806792022 @default.
- W2801280679 countsByYear W28012806792023 @default.
- W2801280679 crossrefType "journal-article" @default.
- W2801280679 hasAuthorship W2801280679A5003880874 @default.
- W2801280679 hasAuthorship W2801280679A5004751576 @default.
- W2801280679 hasAuthorship W2801280679A5013738913 @default.
- W2801280679 hasAuthorship W2801280679A5015397147 @default.
- W2801280679 hasAuthorship W2801280679A5027291703 @default.
- W2801280679 hasAuthorship W2801280679A5029079877 @default.
- W2801280679 hasAuthorship W2801280679A5042074794 @default.
- W2801280679 hasAuthorship W2801280679A5048377473 @default.
- W2801280679 hasAuthorship W2801280679A5051880625 @default.
- W2801280679 hasAuthorship W2801280679A5090658899 @default.
- W2801280679 hasAuthorship W2801280679A5090699665 @default.
- W2801280679 hasConcept C126322002 @default.
- W2801280679 hasConcept C15744967 @default.
- W2801280679 hasConcept C162324750 @default.
- W2801280679 hasConcept C165556158 @default.
- W2801280679 hasConcept C168563851 @default.
- W2801280679 hasConcept C24998067 @default.
- W2801280679 hasConcept C2776867660 @default.
- W2801280679 hasConcept C2778581513 @default.
- W2801280679 hasConcept C548259974 @default.
- W2801280679 hasConcept C71924100 @default.
- W2801280679 hasConceptScore W2801280679C126322002 @default.
- W2801280679 hasConceptScore W2801280679C15744967 @default.
- W2801280679 hasConceptScore W2801280679C162324750 @default.
- W2801280679 hasConceptScore W2801280679C165556158 @default.
- W2801280679 hasConceptScore W2801280679C168563851 @default.